Hybridize Therapeutics

Who we are


Hybridize Therapeutics (2019) is a biotech spin-off from the Leiden University Medical Center with a rich history in research & development in RNA-based therapies. Hybridize’s goal is to help patients overcome untreated diseases. We do this by developing RNA-based therapies, i.e. antisense oligonucleotides. Currently, we are in the pre-clinical phase for our therapy against BK-virus and in the early pre-clinical phase for our therapy against JC-virus. Both viruses are activated in the kidney, the location where our antisense oligonucleotides naturally home to.

READ MORE

Hybridize Therapeutics mission


We feel responsible to help patients overcome untreated diseases with RNA-based therapies

Our Pipeline

Watch here, the interview with the Nierstichting about HYB-BKV.


Latest Publication


‘We waren verrast toen dit idee bleek te werken’

Source nemokennislink.nl

Read article